A few important clues to the mechanisms responsible for the cardiorenal benefits can be gleaned from the recently completed DAPA-HF trial. In this trial, the observed reduction in the primary outcome (time to first event of either cardiovascular death or worsening heart failure) was reduced significantly by 26% in people with heart failure and reduced ejection fraction. Importantly, this benefit was consistent, in those individuals with and those without diabetes, and persisted when evaluated by baseline glycosylated hemoglobin (HbA 1C ) both categorically and continuously. Although the primary renal outcome in the DAPA-HF trial was numerically but not statistically significantly reduced, a closer look at the temporal estimated glomerular filtration rate (eGFR) suggests that participants with and without diabetes exhibited similar initial declines in eGFR. Furthermore, the broad renal composite outcome was numerically lower in those individuals with and those without diabetes. Finally, the heart failure benefits in the groups with and without diabetes were similar, even though the HbA 1C in the latter was essentially unchanged during the trial. Therefore, it is reasonable
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